{"url_path":"/sec/rxst/8-k/2026-06-16/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1111485/0001193125-26-272688-index.html","accession_number":"0001193125-26-272688","cik":"0001111485","ticker":"RXST","issuer_name":"RxSight, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1111485/0001193125-26-272688-index.html","primary_entity_key":"0001111485","primary_entity_name":"RxSight, Inc."},"word_count":306,"has_tables":true,"body_markdown":"##  \n\n## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\n \n\nWe held our 2026 Annual Meeting of Stockholders (“Annual Meeting”) on June 16, 2026. Of the 41,396,609 shares of our common stock outstanding as of April 21, 2026, 33,299,192 shares of common stock were represented, either by attending the virtual annual meeting or by proxy, constituting, of the shares entitled to vote, approximately 80.4% of the outstanding shares of common stock. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below.\n\n \n\n1.\nElection of Three Class II Directors. The following nominees were re-elected by the holders of our common stock to serve as our Class II directors to hold office until our 2029 annual meeting of stockholders and until their successors have been duly elected and qualified:\n\nNominee\n\n \n\nFor\n\n \n\n \n\nAgainst\n\n \n\n \n\nAbstain\n\n \n\n \n\nBroker Non-Votes\n\n \n\nWilliam J. Link\n\n \n\n \n\n21,086,793\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n2,935,396\n\n \n\n \n\n \n\n9,277,003\n\n \n\nRobert Warner\n\n \n\n \n\n15,667,180\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n8,355,009\n\n \n\n \n\n \n\n9,277,003\n\n \n\nShweta Singh Maniar\n\n \n\n \n\n13,850,389\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n10,171,800\n\n \n\n \n\n \n\n9,277,003\n\n \n\n2.\nAdvisory Vote on Executive Compensation. The stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement based on the following results of voting:\n\nFor\n\n \n\n \n\nAgainst\n\n \n\n \n\nAbstain\n\n \n\n \n\nBroker Non-Votes\n\n \n\n \n\n21,236,615\n\n \n\n \n\n \n\n2,742,189\n\n \n\n \n\n \n\n43,385\n\n \n\n \n\n \n\n9,277,003\n\n \n\n3.\nRatification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:\n\nFor\n\n \n\n \n\nAgainst\n\n \n\n \n\nAbstain\n\n \n\n \n\nBroker Non-Votes\n\n \n\n \n\n33,062,585\n\n \n\n \n\n \n\n92,653\n\n \n\n \n\n \n\n143,954\n\n \n\n \n\n \n\n—\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nRxSight, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 16, 2026\n\nBy:\n\n/s/ Mark Wilterding\n\n \n\n \n\n \n\nName: Mark Wilterding\nTitle: Chief Financial Officer"}